补体抑制剂依库珠单抗治疗血栓性微血管病：单中心病例系列

Complement inhibitor eculizumab in thrombotic microangiopathy: Single-center case series.

作者信息

Vitkauskaitė Monika, Vinikovas Artūras, Miglinas Marius, Rimševičius Laurynas, Čerkauskaitė Agnė, Mačionienė Ernesta, Ašakienė Eglė

机构信息

Faculty of Medicine Vilnius University Vilnius Lithuania.

Clinic of Gastroenterology, Nephro-Urology and Surgery Faculty of Medicine Institute of Clinical Medicine Vilnius University Vilnius Lithuania.

出版信息

Clin Case Rep. 2022 Mar 15;10(3):e05573. doi: 10.1002/ccr3.5573. eCollection 2022 Mar.

DOI:10.1002/ccr3.5573

PMID:35317070

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8922540/

Abstract

Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.

摘要

我们的病例系列研究表明，依库珠单抗在治疗血栓性微血管病方面有效且安全，并且对生活质量有积极影响。需要进一步开展广泛研究以制定统一的治疗指南。

相似文献

[1]

Complement inhibitor eculizumab in thrombotic microangiopathy: Single-center case series.

Clin Case Rep. 2022-3-15

[2]

Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.

J Med Case Rep. 2014-9-14

[3]

Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab.

Exp Hematol Oncol. 2017-1-13

[4]

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

N Engl J Med. 2013-6-6

[5]

A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.

Kidney Int. 2024-5

[6]

The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.

Kidney Int. 2021-7

[7]

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.

Kidney Int. 2020-6

[8]

[Ocular thrombotic microangiopathy in atypical hemolytic-uremic syndrome (a clinical case study)].

Vestn Oftalmol. 2018

[9]

When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.

Am J Nephrol. 2018-8-15

[10]

Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.

Transfus Apher Sci. 2016-12

本文引用的文献

[1]

Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review.

Front Immunol. 2021-11-10

[2]

Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab.

Clin Kidney J. 2020-6-22

[3]

Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort.

J Nephrol. 2022-3

[4]

Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review.

Clin Epidemiol. 2020-3-12

[5]

Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry.

Kidney Int Rep. 2019-8-2

[6]

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.

BMC Nephrol. 2019-4-10

[7]

Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome.

Kidney Int Rep. 2018-12-3

[8]

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Clin Pharmacokinet. 2019-7

[9]

Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.

Pediatr Nephrol. 2019-5

[10]

Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.

Semin Arthritis Rheum. 2018-12-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

补体抑制剂依库珠单抗治疗血栓性微血管病：单中心病例系列

Complement inhibitor eculizumab in thrombotic microangiopathy: Single-center case series.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献